Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates
The fabrication and development of nanomaterials for the treatment of prostate cancer have gained significant appraisal in recent years. Advancements in synthesis of organic and inorganic nanomaterials with charge, particle size, specified geometry, ligand attachment etc have resulted in greater bio...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Nanomaterials |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-4991/10/9/1696 |
_version_ | 1797555230435442688 |
---|---|
author | Mahmood Barani Fakhara Sabir Abbas Rahdar Rabia Arshad George Z. Kyzas |
author_facet | Mahmood Barani Fakhara Sabir Abbas Rahdar Rabia Arshad George Z. Kyzas |
author_sort | Mahmood Barani |
collection | DOAJ |
description | The fabrication and development of nanomaterials for the treatment of prostate cancer have gained significant appraisal in recent years. Advancements in synthesis of organic and inorganic nanomaterials with charge, particle size, specified geometry, ligand attachment etc have resulted in greater biocompatibility and active targeting at cancer site. Despite all of the advances made over the years in discovering drugs, methods, and new biomarkers for cancer of the prostate (PCa), PCa remains one of the most troubling cancers among people. Early on, effective diagnosis is an essential part of treating prostate cancer. Prostate-specific antigen (PSA) or serum prostate-specific antigen is the best serum marker widely accessible for diagnosis of PCa. Numerous efforts have been made over the past decade to design new biosensor-based strategies for biomolecules detection and PSA miniaturization biomarkers. The growing nanotechnology is expected to have a significant effect in the immediate future on scientific research and healthcare. Nanotechnology is thus predicted to find a way to solve one of the most and long-standing problem, “early cancer detection”. For early diagnosis of PCa biomarkers, different nanoparticles with different approaches have been used. In this review, we provide a brief description of the latest achievements and advances in the use of nanoparticles for PCa biomarker diagnosis. |
first_indexed | 2024-03-10T16:44:31Z |
format | Article |
id | doaj.art-08720676212a4dc49808152b1ce48e19 |
institution | Directory Open Access Journal |
issn | 2079-4991 |
language | English |
last_indexed | 2024-03-10T16:44:31Z |
publishDate | 2020-08-01 |
publisher | MDPI AG |
record_format | Article |
series | Nanomaterials |
spelling | doaj.art-08720676212a4dc49808152b1ce48e192023-11-20T11:42:16ZengMDPI AGNanomaterials2079-49912020-08-01109169610.3390/nano10091696Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent UpdatesMahmood Barani0Fakhara Sabir1Abbas Rahdar2Rabia Arshad3George Z. Kyzas4Department of Chemistry, Shahid Bahonar University of Kerman, Kerman 7616914111, IranInstitute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, HungaryDepartment of Physics, Faculty of Science, University of Zabol, Zabol 538-98615, IranDepartment of Pharmacy, Quaid-i-Azam University, Islamabad 45320, PakistanDepartment of Chemistry, International Hellenic University, 65404 Kavala, GreeceThe fabrication and development of nanomaterials for the treatment of prostate cancer have gained significant appraisal in recent years. Advancements in synthesis of organic and inorganic nanomaterials with charge, particle size, specified geometry, ligand attachment etc have resulted in greater biocompatibility and active targeting at cancer site. Despite all of the advances made over the years in discovering drugs, methods, and new biomarkers for cancer of the prostate (PCa), PCa remains one of the most troubling cancers among people. Early on, effective diagnosis is an essential part of treating prostate cancer. Prostate-specific antigen (PSA) or serum prostate-specific antigen is the best serum marker widely accessible for diagnosis of PCa. Numerous efforts have been made over the past decade to design new biosensor-based strategies for biomolecules detection and PSA miniaturization biomarkers. The growing nanotechnology is expected to have a significant effect in the immediate future on scientific research and healthcare. Nanotechnology is thus predicted to find a way to solve one of the most and long-standing problem, “early cancer detection”. For early diagnosis of PCa biomarkers, different nanoparticles with different approaches have been used. In this review, we provide a brief description of the latest achievements and advances in the use of nanoparticles for PCa biomarker diagnosis.https://www.mdpi.com/2079-4991/10/9/1696nanomaterialscancerprostatetreatmentdiagnosis |
spellingShingle | Mahmood Barani Fakhara Sabir Abbas Rahdar Rabia Arshad George Z. Kyzas Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates Nanomaterials nanomaterials cancer prostate treatment diagnosis |
title | Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates |
title_full | Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates |
title_fullStr | Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates |
title_full_unstemmed | Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates |
title_short | Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates |
title_sort | nanotreatment and nanodiagnosis of prostate cancer recent updates |
topic | nanomaterials cancer prostate treatment diagnosis |
url | https://www.mdpi.com/2079-4991/10/9/1696 |
work_keys_str_mv | AT mahmoodbarani nanotreatmentandnanodiagnosisofprostatecancerrecentupdates AT fakharasabir nanotreatmentandnanodiagnosisofprostatecancerrecentupdates AT abbasrahdar nanotreatmentandnanodiagnosisofprostatecancerrecentupdates AT rabiaarshad nanotreatmentandnanodiagnosisofprostatecancerrecentupdates AT georgezkyzas nanotreatmentandnanodiagnosisofprostatecancerrecentupdates |